Growth Metrics

Keros Therapeutics (KROS) Other Working Capital Changes (2019 - 2025)

Keros Therapeutics filings provide 7 years of Other Working Capital Changes readings, the most recent being -$4.2 million for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes fell 139.07% to -$4.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.0 million, a 139.33% decrease, with the full-year FY2025 number at -$4.0 million, down 139.33% from a year prior.
  • Other Working Capital Changes hit -$4.2 million in Q4 2025 for Keros Therapeutics, down from -$770000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $10.7 million in Q4 2024 to a low of -$9.3 million in Q4 2023.
  • Median Other Working Capital Changes over the past 5 years was -$491000.0 (2024), compared with a mean of $434263.2.
  • Biggest five-year swings in Other Working Capital Changes: tumbled 1188.89% in 2022 and later skyrocketed 656.86% in 2023.
  • Keros Therapeutics' Other Working Capital Changes stood at $46000.0 in 2021, then plummeted by 3934.78% to -$1.8 million in 2022, then plummeted by 429.76% to -$9.3 million in 2023, then surged by 214.31% to $10.7 million in 2024, then crashed by 139.07% to -$4.2 million in 2025.
  • The last three reported values for Other Working Capital Changes were -$4.2 million (Q4 2025), -$770000.0 (Q3 2025), and -$2.4 million (Q2 2025) per Business Quant data.